Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era.
Toss A, Isca C, Venturelli M, Nasso C, Ficarra G, Bellelli V, Armocida C, Barbieri E, Cortesi L, Moscetti L, Piacentini F, Omarini C, Andreotti A, Gambini A, Battista R, Dominici M, Tazzioli G. Toss A, et al. Among authors: isca c. ESMO Open. 2021 Apr;6(2):100055. doi: 10.1016/j.esmoop.2021.100055. Epub 2021 Feb 12. ESMO Open. 2021. PMID: 33582382 Free PMC article.
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients.
Del Re M, Omarini C, Diodati L, Palleschi M, Meattini I, Crucitta S, Lorenzini G, Isca C, Fontana A, Livi L, Piacentini F, Fogli S, De Giorgi U, Danesi R. Del Re M, et al. Among authors: isca c. ESMO Open. 2021 Oct;6(5):100231. doi: 10.1016/j.esmoop.2021.100231. Epub 2021 Sep 9. ESMO Open. 2021. PMID: 34509802 Free PMC article.
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients.
Del Re M, Omarini C, Diodati L, Palleschi M, Meattini I, Crucitta S, Lorenzini G, Isca C, Fontana A, Livi L, Piacentini F, Fogli S, De Giorgi U, Danesi R. Del Re M, et al. Among authors: isca c. ESMO Open. 2022 Feb;7(1):100381. doi: 10.1016/j.esmoop.2022.100381. Epub 2022 Feb 4. ESMO Open. 2022. PMID: 35131649 Free PMC article. No abstract available.
Molecular Pathways of Breast Cancer in Systemic Sclerosis: Exploratory Immunohistochemical Analysis from the Sclero-Breast Study.
Isca C, Spinella A, Toss A, de Pinto M, Ficarra G, Fabbiani L, Iannone A, Magnani L, Lumetti F, Macripò P, Vacchi C, Gasparini E, Piana S, Cortesi L, Maiorana A, Salvarani C, Dominici M, Giuggioli D. Isca C, et al. J Pers Med. 2022 Dec 3;12(12):2007. doi: 10.3390/jpm12122007. J Pers Med. 2022. PMID: 36556228 Free PMC article.
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials.
Omarini C, Piacentini F, Sperduti I, Barbolini M, Isca C, Toss A, Cortesi L, Barbieri E, Dominici M, Moscetti L. Omarini C, et al. Among authors: isca c. BMC Cancer. 2020 May 13;20(1):418. doi: 10.1186/s12885-020-06933-y. BMC Cancer. 2020. PMID: 32404154 Free PMC article.
16 results